GELS vs ZTS vs TEVA Stock Comparison

Gelteq, Zoetis and Teva Pharmaceutical Industries Prices as of Nov 16, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.36 -20.0% 1M -63.9% 1Y
Market cap
$2.43M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
ZTS Zoetis Inc.
$84.43 +6.4% 1M -30.1% 1Y
Market cap
$34.44B
P/E
13.7x
Revenue (TTM)
$9.49B
Div. yield
0.03%
Animal Health Healthcare
6 wins

Head to Head

11 decided of 12

Zoetis leads on 6 of the 12 questions below (Zoetis 6, Teva Pharmaceutical Industries 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSZTSTEVALeader
Larger companyMarket capitalisation $2.43M $34.44B $49.60B TEVA
Cheaper on earningsLower P/E, profitable companies only — 13.7x 98.0x ZTS
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 14.1x 22.7x ZTS
Faster revenue growthRevenue growth, trailing twelve months — +0.9% +2.7% TEVA
More profitableNet margin, trailing twelve months — 26.4% 2.9% ZTS
Better return on capitalReturn on invested capital — 23.0% 5.9% ZTS
Less leveragedLower net debt / EBITDA — 1.9x 5.2x ZTS
Higher dividend yieldTrailing dividend yield 0.00% 0.03% 0.00% –
Better 1-year returnPrice return, last 12 months -63.9% -30.1% +67.6% TEVA
Better 5-year returnAnnualised price return, 5 years — -17.6%/yr +36.0%/yr TEVA
Less volatileAnnualised volatility, 1 year 160.3% 39.7% 33.6% TEVA
Higher overall scoreMean of the five percentile scores vs peers — 69/100 62/100 ZTS

Percentile Scorecard

GELSZTSTEVA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSZTSTEVA
Valuation – 85 #98 of 659 82 #117 of 659
Growth – 45 #339 of 617 68 #200 of 617
Profitability – 97 #20 of 593 86 #83 of 593
Financial Health 58 #6 of 13 31 #469 of 680 11 #607 of 680
Shareholder Returns – 85 #68 of 459 –
Overall – 69 62
  • GELS ranked among 13 companies in Pharma Services
  • ZTS ranked among 693 companies in Pharmaceuticals and Biotechnology
  • TEVA ranked among 693 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSZTSTEVASPY
1 month -20.0%+6.4%+2.7% -3.0%
3 months -35.7%+15.7%+16.8% -4.2%
6 months -11.1%+8.6%+25.2% +0.2%
Year to date -55.0%-32.9%+36.5% +8.5%
1 year -63.9%-30.1%+67.6% +10.1%
3 years —-51.7%+370.6% +64.1%
3 years, per year —-21.6%+67.6% +18.0%
5 years —-61.9%+365.0% +58.1%
5 years, per year —-17.6%+36.0% +9.6%
10 years —+72.9%+11.9% +239.6%
10 years, per year —+5.6%+1.1% +13.0%

Risk

MeasureGELSZTSTEVASPY
Volatility, 1Y 160.3%39.7%33.6% 13.8%
Downside volatility, 1Y 124.2%46.9%28.0% 14.2%
Beta vs S&P 500, 1Y 1.810.580.61 1.00
Return / volatility, 1Y -0.40-0.762.01 0.74
Max drawdown, 5Y -92.5%-72.0%-43.7% -25.4%
From 52-week high -76.5%-35.6%-4.4% -5.0%
52-week high $1.53$131.10$44.54 $779.14
52-week low $0.36$69.12$24.21 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSZTSTEVA
P/E now vs peer median —median 34.7x 13.8xmedian 17.1x 102.6xmedian 17.1x
P/S now vs peer median —median 2.5x 3.6xmedian 8.3x 3.0xmedian 8.3x
EV/EBITDA now vs peer median —median 29.1x 10.4xmedian 15.1x 26.7xmedian 15.1x
P/FCF now vs peer median -5.7xmedian 21.0x 15.3xmedian 18.1x 42.0xmedian 18.1x
P/B now vs peer median 0.4xmedian 1.6x 10.3xmedian 2.0x 6.5xmedian 2.0x
PEG now vs peer median —median 1.98 1.91median 0.43 3.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSZTSTEVA
Revenue – $9.49B $17.23B
Gross profit – $6.80B $9.22B
Operating income – $3.54B $1.44B
Net income – $2.51B $508.00M
Free cash flow – $2.24B $1.24B
R&D – $722.00M $1.76B
EPS (diluted) – $6.09 $0.43
Cash & equivalents $6.26K $1.33B $4.09B
Total debt $9.08K $9.05B $16.72B
Shares (diluted) 9.27M 411.60M 1.18B
Enterprise value $283.86K $26.84B $34.56B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSZTSTEVA
P/E – 13.8x 102.6x
P/FCF -5.7x 15.3x 42.0x
P/Operating cash flow – 12.5x 29.4x
P/S – 3.6x 3.0x
P/B 0.4x 10.3x 6.5x
P/Tangible book -1.2x 13.9x 11.1x
EV/EBITDA – 10.4x 26.7x
EV/EBIT – 11.8x 45.0x
EV/Revenue – 4.4x 3.7x
EV/FCF – 18.6x 52.3x
EV/Operating cash flow – 15.3x 36.5x
PEG (3Y EPS CAGR) – 1.91 3.39

Growth

14 metrics
MetricGELSZTSTEVA
Revenue growth (1Y) – 0.9% 2.7%
Revenue CAGR (3Y) – 4.3% 4.1%
Gross profit growth (1Y) – 1.0% 9.7%
Gross profit CAGR (3Y) – 4.9% 9.6%
Operating income growth (1Y) – -1.7% -21.5%
Operating income CAGR (3Y) – 4.0% 46.4%
Net income growth (1Y) – -4.7% -23.3%
Net income CAGR (3Y) – 3.2% 30.3%
EPS growth (1Y) – 2.6% -30.1%
EPS CAGR (3Y) – 7.2% 30.2%
Operating cash flow growth (1Y) – -7.9% 66.0%
Operating cash flow CAGR (3Y) – 7.5% 15.2%
Free cash flow growth (1Y) – -2.1% 113.8%
Free cash flow CAGR (3Y) – 14.4% 26.7%

Profitability

14 metrics
MetricGELSZTSTEVA
Gross margin – 71.6% 53.5%
EBITDA margin – 42.4% 14.0%
Operating margin – 37.3% 8.3%
Pretax margin – 33.1% 2.1%
Net margin – 26.4% 2.9%
FCF margin – 23.5% 7.2%
Operating cash flow margin – 28.7% 10.3%
Return on equity – 77.7% 6.5%
Return on assets – 16.6% 1.3%
Return on invested capital – 23.0% 5.9%
Return on capital employed – 28.6% 5.9%
Asset turnover – 0.6x 0.4x
Cash conversion (OCF / net income) – 1.1x 3.5x
Stock comp / revenue – 1.1% 1.0%

Financial Health

11 metrics
MetricGELSZTSTEVA
Debt / assets 0.1% 60.0% 41.8%
Debt / equity 0.0x 2.7x 2.1x
Net debt / EBITDA – 1.9x 5.2x
Debt / FCF – 4.0x 13.5x
Liabilities / assets 29.4% 78.1% 80.1%
Equity / assets 70.6% 21.9% 19.9%
Interest coverage – 14.6x –
Current ratio 0.1x 2.3x 0.9x
Quick ratio 0.1x 1.2x 0.5x
Cash ratio 0.0x 0.6x 0.3x
Altman Z-score – 4.85 1.02

Shareholder Returns

7 metrics
MetricGELSZTSTEVA
Dividend yield – 2.5% –
Net buyback yield – 11.0% –
Shareholder yield – 13.5% 0.0%
Payout ratio (earnings) – 35.3% –
Payout ratio (FCF) – 39.6% –
Dividend growth (1Y) – 2.7% –
Dividend CAGR (3Y) – 9.7% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSZTSTEVA
Forward P/E – 14.1xFY2026 22.7xFY2026
EPS, next fiscal year – $5.96FY2026 $1.96FY2026
EPS growth, next FY – -7.0%FY2026 -33.1%FY2026
EPS growth, the year after – +10.1% +65.3%
Revenue, next fiscal year – $9.59BFY2026 $15.89BFY2026
Revenue growth, next FY – +1.3%FY2026 -8.0%FY2026
Revenue growth, the year after – -9.0% +16.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSZTSTEVA
Held by institutions – 94.7% 62.7%
Institutions holding – 1,419 672
Change in shares held, QoQ – -2.6% +8.6%
Institutions buying – 674 359
Institutions selling – 584 192
Buyers to sellers – 1.15 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSZTSTEVA
GELS 1.00 0.03 0.02
ZTS 0.03 1.00 0.12
TEVA 0.02 0.12 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS, ZTS and TEVA?

Teva Pharmaceutical Industries (TEVA) is the largest by market capitalisation: Gelteq (GELS) $2.43M, Zoetis (ZTS) $34.44B, Teva Pharmaceutical Industries (TEVA) $49.60B.

Which stock is cheaper, GELS, ZTS and TEVA?

Zoetis (ZTS) trades on the lowest price-to-earnings ratio (Zoetis (ZTS) 13.7x, Teva Pharmaceutical Industries (TEVA) 98.0x). On next year's consensus earnings, Zoetis (ZTS) is cheapest (Zoetis (ZTS) 14.1x, Teva Pharmaceutical Industries (TEVA) 22.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Teva Pharmaceutical Industries (TEVA) grew revenue fastest over the trailing twelve months: Zoetis (ZTS) +0.9%, Teva Pharmaceutical Industries (TEVA) +2.7%.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Zoetis (ZTS) 26.4%, Teva Pharmaceutical Industries (TEVA) 2.9%). On return on invested capital, Zoetis (ZTS) leads (Zoetis (ZTS) 23.0%, Teva Pharmaceutical Industries (TEVA) 5.9%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Gelteq (GELS) -63.9%, Zoetis (ZTS) -30.1%, Teva Pharmaceutical Industries (TEVA) +67.6%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Zoetis (ZTS) -17.6%/yr, Teva Pharmaceutical Industries (TEVA) +36.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Gelteq (GELS) 0.00%, Zoetis (ZTS) 0.03%, Teva Pharmaceutical Industries (TEVA) 0.00%. Gelteq (GELS) and Teva Pharmaceutical Industries (TEVA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Teva Pharmaceutical Industries (TEVA) has been the steadiest (Gelteq (GELS) 160.3%, Zoetis (ZTS) 39.7%, Teva Pharmaceutical Industries (TEVA) 33.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GELS, ZTS and TEVA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.